Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Unknown 23Recruiting 18Not yet recruiting 12Completed 4Active not recruiting 3Suspended 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 3Thoracic 1

Conditions

Solid Tumors 2Carcinoma, Non-Small-Cell Lung 1Advanced or Metastatic Solid Tumors 1

Interventions

Cyclophosphamide 1488Cisplatin 1410Paclitaxel 1316Radiotherapy 1259Carboplatin 1247Gemcitabine 1214Docetaxel 1110Bevacizumab 1029Fluorouracil 894Doxorubicin 786Dexamethasone 746Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 673Etoposide 673Irinotecan 634Filgrastim 621Cytarabine 584Leucovorin 578Nivolumab 557Vincristine 510Prednisone 474Cetuximab 464Bortezomib 457Erlotinib Hydrochloride 456Trastuzumab 448Methotrexate 437Lenalidomide 426Pemetrexed 419

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Interventional × envafolimab × Clear all
NCT05068427 2024-08-07

Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.

Chipscreen Biosciences, Ltd.

Phase 2 Completed
34 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03101488 2022-03-03

Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors

3D Medicines

Phase 1 Completed
287 enrolled
Other solid neoplasm

Solid Tumors

NCT03248843 2022-02-08

A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors

3D Medicines

Phase 1 Completed
35 enrolled
Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT02827968 2021-06-02

Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors

3D Medicines

Phase 1 Completed
28 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡